P1.03-33 Mutational Spectrum and Prognosis of Non-Small-Cell Lung Cancer Harboring MTOR Mutations in Chinese Population

C. Xu,W. Wang,Q. Zhang,W. Zhuang,Y. Zhu,Y. Chen,M. Fang,G. Chen,T. Lv,Y. Song

DOI: https://doi.org/10.1016/j.jtho.2018.08.714

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:Mammalian Target of Rapamycin (mTOR) is a validated target in cancer. It remains to be determined whether non-small-cell lung cancer patients bearing mTOR mutation could be selected for treatment with PI3K-AKT-mTOR pathway inhibitors. While the genetic spectrum of MTOR mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring MTOR mutations. A total of 639 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of MTOR mutation and other genes were detected by next generation sequencing. MTOR gene mutation rate was 3.60% (23/639) in non-small cell lung cancer, including T1830_T1833[2>1] (3 patients), S221N (1 patient), C1483F (1 patient), D1527H (1 patient), I1964V (1 patient), E1799K (1 patient), L88F (1 patient), P2273L (1 patient), E97K (1 patient), L565Q (1 patient), M1038I (1 patient), A1792V (1 patient), R1896Q (1 patient), G1678E (1 patient), M2327I (1 patient), E2419K (1 patient), A2248S (1 patient), T1870S (1 patient), V2198A (1 patient), R1482P (1 patient) and E1362K (1 patient), and median overall survival (OS) for these patients was 13.0 months. Among them, all patients were MTOR gene with co-occurring mutation. Briefly, patients with (n=5) or without (n=18) co-occurring EGFR mutations had a median OS of 17.0 months and 11.0 months respectively (P=0.33); patients with (n=15) or without (n=8) co-occurring TP53 mutations had a median OS of 11.0 months and 13.0 months respectively (P=0.42). MTOR mutation may predict a worse prognosis of NSCLC. MTOR pathway inhibitors everolimus may be beneficial for NSCLC patients with specific MTOR mutations. EGFR and TP53 gene accompanied may have less correlation with MTOR mutation in NSCLC patients. The findings of this study could facilitate both clinical trial design and therapeutic strategies.